Fact-checked by Grok 2 weeks ago

Bartonella henselae

Bartonella henselae is a fastidious, intracellular Gram-negative that primarily causes (), a self-limiting zoonotic most commonly transmitted through scratches, bites, or licks from domestic or feral cats, particularly kittens, whose claws or saliva may be contaminated with feces harboring the . This bacterium is acquired by cats via bites from Ctenocephalides felis, and up to one in three healthy cats, especially young ones, may carry B. henselae asymptomatically, making it a widespread worldwide. CSD typically manifests 1–3 weeks after exposure with a or pustule at the site, followed by regional , low-grade fever, and fatigue, affecting approximately 55% of cases in children under 18 years and peaking in fall and winter in the United States. In immunocompetent individuals, the infection often resolves spontaneously within months, but dissemination can lead to complications such as ocular involvement (e.g., Parinaud's oculoglandular syndrome), , or visceral abscesses in the liver or ; in immunocompromised patients, it may cause more severe conditions like bacillary angiomatosis or . relies on clinical history, serologic testing (e.g., or indirect immunofluorescence), and occasionally or , as cultures are challenging due to the bacterium's fastidious nature. Treatment for mild cases involves supportive care, while antibiotics such as are recommended for severe or disseminated disease to alleviate symptoms, though they do not always shorten overall duration; prevention focuses on avoiding cat scratches, prompt wound cleaning, control in cats, and keeping felines indoors.

Microbiology

Characteristics

Bartonella henselae is a Gram-negative, facultative intracellular bacterium classified within the Bartonellaceae of the Rhizobiales. This fastidious thrives as an , exhibiting a unique lifestyle that involves intracellular persistence within host cells while evading immune detection. Morphologically, B. henselae presents as pleomorphic rods, typically measuring 0.3–0.6 μm in width and 1.0–1.7 μm in length, often appearing slightly curved or comma-shaped. In , these bacteria form clumps or chains, contributing to their characteristic aggregation on host cells and media. The organism lacks and does not produce spores, further defining its non-flagellated, inert profile under standard conditions. Growth of B. henselae is notably slow and requires enriched media, such as , incubated aerobically at 35–37°C with 5% CO₂; visible colonies typically emerge after 3–21 days. These colonies are small, gray-white, and adherent to the agar surface, reflecting the bacterium's fastidious nature and dependence on or blood supplementation for optimal proliferation. Biochemically, B. henselae is - and catalase-variable (usually negative), non-fermentative, utilizes glucose oxidatively but not , and is urease-negative. A distinctive feature of B. henselae is its adhesion to erythrocytes via the Trw type IV secretion system and to endothelial cells through pili, enabling host cell invasion and persistent infection, particularly in feline reservoirs.

Genome and Genetics

The genome of Bartonella henselae comprises a single circular measuring approximately 1.9 Mb, with the reference Houston-1 strain fully sequenced in 2004 revealing a of 1,931,047 bp. This strain exhibits typical genomic features of the species, including a G+C content of about 38% and approximately 1,500 protein-coding genes, of which around 1,491 are orthologous to those in related species. Strain-specific variations occur, particularly in regions of genomic islands and mobile elements, contributing to differences in gene content across isolates from cats and humans. Key virulence factors are encoded within the , including the badA gene, which produces a trimeric autotransporter adhesin responsible for bacterial autoagglutination, binding, and formation on host cells. Another critical element is the virB , comprising 10 genes that form a type IV secretion system essential for injecting effector proteins into host endothelial cells, thereby facilitating bacterial invasion and intracellular persistence. Plasmids are rare in B. henselae isolates, with no native plasmids identified in the standard Houston-1 . Genomic plasticity is driven by and insertion sequences, which mediate rearrangements, deletions, and amplifications, particularly near the replication terminus; analysis of 38 revealed 106 such events, often linked to prophage regions like the . diversity is characterized by three main (I, II, and III), distinguished via the 16S-23S rRNA intergenic spacer region, with genotype I associated with higher in human infections. Regarding , B. henselae exhibits intrinsic resistance to penicillin, while genes encoding potential efflux pumps may further contribute to multidrug tolerance.

Transmission and Pathogenesis

Transmission Routes

_Bartonella henselae is primarily transmitted zoonotically from (Felis catus), the main reservoir host, to humans through direct contact such as scratches, bites, or licks on open wounds. The bacterium is carried on cat claws contaminated with flea feces or in saliva, facilitating entry through broken skin or mucous membranes. Cat fleas (Ctenocephalides felis) serve as mechanical vectors, ingesting the bacteria during blood meals from infected and excreting them in feces, which can remain infectious for up to 12 days. In cats, B. henselae causes bacteremia in 4–60% of healthy domestic cats worldwide, with higher rates in kittens, , and certain regions due to exposure and immature immune systems. The infection persists for weeks to months, and occasionally up to 2–3 years, allowing cats to serve as long-term reservoirs. Cat-to-cat occurs primarily via fleas, which mechanically transfer the through bites or scratches, rather than direct contact or . Human exposure typically involves close interaction with infected , particularly kittens or those in flea-infested environments, leading to via contaminated or claws. Rare human-to-human has been documented in case reports, including through transfusions and solid organ transplants from infected donors. The bacterium survives poorly outside of hosts or vectors, with viability in environmental fluids like saline or limited to hours to 7 days, and no established airborne or waterborne routes. B. henselae is distributed worldwide, but is more prevalent in warm, humid climates that favor flea proliferation and year-round activity.

Infection Mechanisms

_Bartonella henselae initiates infection through host-specific mechanisms that target erythrocytes and endothelial cells. The Trw type IV (T4SS) facilitates to erythrocytes, enabling host and bloodstream without of the host cell. Concurrently, the BadA trimeric autotransporter adhesin promotes attachment to endothelial cells by binding proteins such as via β1-integrins, triggering cytoskeletal rearrangements that support bacterial aggregation on the cell surface. These events induce resistance to host cell , allowing prolonged bacterial interaction and entry. Following adhesion, B. henselae achieves intracellular survival by deploying the VirB/VirD4 T4SS to inject a repertoire of Bartonella effector proteins (Beps, such as BepA-G) into host cells. These effectors, characterized by motifs like FIC domains for AMPylation or phosphorylation sites, reorganize the host to form invasomes—specialized F-actin structures that engulf bacterial aggregates into a resistant to lysosomal fusion. This process subverts endocytic pathways, enabling replication within a protected niche in endothelial cells and macrophages while suppressing apoptotic signals through pathways like elevation via BepA-AC7 interaction. Virulence genes encoding the VirB/VirD4 system and Beps represent key adaptations for intracellular persistence, as identified in genomic analyses. Chronic infection elicits a vasculoproliferative response characterized by endothelial and the formation of granulomas or vascular s. BadA and Bep effectors activate hypoxia-inducible factor-1 (HIF-1) and nuclear factor-κB () pathways, stimulating secretion of pro-angiogenic factors such as (VEGF) and interleukin-8 (IL-8), which drive pathological . This response facilitates bacterial and lesion development, particularly in prolonged infections. B. henselae evades host immunity by modulating inflammatory signaling and exploiting erythrocyte niches. It inhibits excessive NF-κB activation to dampen proinflammatory responses, while promoting IL-10 production via BepD-STAT3 interactions to reduce cytokine output like TNF-α. Additionally, the bacterium's lipopolysaccharide acts as a TLR4 antagonist, further limiting cytokine production and dendritic cell activation. Persistence within erythrocytes provides a stealth reservoir, as intraerythrocytic bacteria avoid phagocytosis, complement activation, and MHC presentation without lysing the cell. The infection progresses in distinct phases: an initial acute bacteremia phase, where bacteria seed the bloodstream shortly after entry, followed by a latent phase of asymptomatic persistence primarily in erythrocytes and endothelial cells. Periodic relapsing bacteremia occurs during latency, but full reactivation, leading to disseminated disease, is more pronounced in immunocompromised hosts due to impaired immune control. Animal models illuminate these mechanisms. In cats, the primary reservoir, B. henselae rapidly colonizes lymph nodes within hours of inoculation, establishing a persistent infection via lymphatic spread. In human models and observations, the bacterium targets the reticuloendothelial system, including spleen, liver, and bone marrow, supporting systemic dissemination and latency.

Clinical Manifestations

Cat Scratch Disease

() is the most common clinical manifestation of Bartonella henselae infection in immunocompetent individuals, typically presenting as a self-limited regional lymphadenitis following exposure to infected s. The ranges from 1 to 3 weeks after a cat scratch or bite, during which a primary develops at the site of entry in 50% to 90% of cases. This appears as a painless , pustule, or vesicle, often erythematous and measuring 2 to 5 mm in diameter, and it usually resolves within 1 to 3 weeks without intervention. The hallmark feature of CSD is tender regional , which emerges 1 to 3 weeks after the primary and affects nodes draining the , such as axillary nodes for arm scratches or cervical nodes for facial exposure. These nodes are typically enlarged (1 to 5 cm), solitary or few in number, and may become fluctuant or suppurative in about 10% to 15% of cases, though suppuration rarely requires . persists for 2 to 4 months in most patients, occasionally extending up to 8 months, and resolves spontaneously without scarring. Accompanying systemic symptoms occur in approximately 30% of cases and include mild fever (often low-grade, lasting a few days), , , and anorexia, contributing to the overall subacute course of the illness. Histologically, affected lymph nodes exhibit stellate granulomas characterized by central surrounded by palisading histiocytes, lymphocytes, and multinucleated giant cells, often forming microabscesses that reflect the necrotizing suppurative response to bacterial . predominantly affects children, particularly those aged 5 to 9 years, who experience the highest incidence rates. The disease is self-limiting in the vast majority of immunocompetent hosts, with full resolution typically occurring within 2 to 8 weeks for acute symptoms and up to 4 months for , without specific in mild cases. Rare complications, such as or , arise in 1% to 5% of patients and may prolong recovery, though most affected individuals experience no long-term sequelae.

Other Associated Conditions

Bacillary angiomatosis is a vascular proliferative disorder primarily caused by Bartonella henselae in immunocompromised individuals, particularly those with and CD4 counts below 100 cells/mm³. It manifests as reddish-purple papules or nodules on the skin, often resembling , and can involve visceral organs such as the liver, , or nodes, leading to systemic symptoms like fever and weight loss. Histologically, these lesions show neovascular proliferation with bacterial clumps visible on Warthin-Starry stain. Bacillary peliosis hepatis, exclusively associated with B. henselae, presents as blood-filled cystic lesions in the liver or in patients with advanced , such as advanced or post-transplant states. Affected individuals may experience , , or due to organ involvement, with imaging revealing hyperechoic lesions on . Untreated cases can lead to organ rupture or . B. henselae endocarditis accounts for a substantial proportion of culture-negative cases, estimated at 12% to 28% in various series, often involving native or prosthetic valves with vegetations detectable by . Clinical features include persistent fever, , and embolic phenomena such as or splenic infarcts, particularly in patients with prior valvular disease or . Diagnosis typically requires serological or confirmation due to the fastidious nature of the organism. Ocular involvement in B. henselae includes neuroretinitis, characterized by unilateral and a macular star pattern of exudates, leading to or central . Parinaud's oculoglandular syndrome features granulomatous with ipsilateral preauricular , occurring in 2% to 7% of cases. , including intermediate forms with , can cause vitritis or serous detachments, potentially resulting in vision loss if untreated. Neurological complications of B. henselae are uncommon, affecting 1% to 7% of cases, with being the most frequent, presenting as seizures, altered mental status, or in pediatric patients. manifests as acute lower limb weakness, sensory deficits, and , confirmed by MRI showing lesions. A rare association with Guillain-Barré syndrome has been reported, involving ascending paralysis responsive to intravenous immunoglobulin. Disseminated B. henselae in immunocompromised hosts, such as solid organ transplant recipients or asplenic patients, often involves multiple organs including , liver, and bone, with as a common initial sign. In transplant settings, it may present as , , or graft dysfunction months post-transplantation, linked to exposure. Untreated disseminated disease carries higher mortality due to complications like multiorgan failure, though overall fatality remains low with prompt antimicrobial therapy.

Epidemiology

Prevalence and Distribution

Bartonella henselae is endemic worldwide, with infections reported across all continents, though incidence is highest in temperate and warm climatic regions where vectors thrive. In the United States, the average annual incidence of , primarily caused by B. henselae, is approximately 4.5 cases per 100,000 population, equating to about 12,500 infections and around 500 hospitalizations each year based on recent estimates. Globally, cases are underreported due to mild symptoms in many instances and diagnostic challenges, but the bacterium's aligns with populations and prevalence, showing peaks in fall and winter corresponding to flea season in affected areas. Seroprevalence of B. henselae in healthy cat populations varies regionally but typically ranges from 20% to 60%, reflecting widespread exposure; rates can reach up to 90% in cats presenting with clinical illness, such as those with fever or . Prevalence is notably higher in multi-cat households, where close facilitates via fleas or direct . Molecular detection indicates that 20% to 40% of cats carry viable B. henselae in their bloodstream, underscoring their role as primary reservoirs. A 2023 meta-analysis estimated the global molecular prevalence of B. henselae in cats at 13.05%, with higher rates in warmer climates. Recent data highlight emerging patterns in and , with increasing reports of B. henselae infections linked to growing pet ownership and . In , prevalence in stray and pet cats has been documented at 5.7% to 65% in various countries, with rising notifications in urban centers like those in . The zoonotic burden is amplified by vectors, where molecular detection of B. henselae ranges from 1% to 10% in cat fleas, facilitating cycles.

Risk Factors and At-Risk Populations

Behavioral risk factors for Bartonella henselae infection primarily involve close contact with cats, particularly through scratches, bites, or licks on broken skin, as the bacteria are transmitted via contaminated cat saliva or flea feces. Exposure to kittens under one year of age is especially hazardous, since approximately 56% of bacteremic cats are in this age group, increasing the likelihood of transmission during play or handling. Owning multiple cats, including strays, further elevates risk. Additionally, households with outdoor cats exposed to fleas represent a key vector pathway, as Ctenocephalides felis serves as the primary arthropod transmitter among cats. Demographically, B. henselae infections, often manifesting as , disproportionately affect children, with 60% of cases occurring in those under 18 years and peak incidence in the 5- to 14-year age group. Immunocompromised individuals face heightened susceptibility to severe or disseminated forms, including those with and counts below 200 cells/μL, as well as solid organ transplant recipients, where impairment allows bacterial persistence and complications like bacillary angiomatosis. Certain occupations increase exposure due to frequent cat interactions. Veterinarians exhibit elevated seropositivity rates for B. henselae, reflecting occupational hazards from handling infected animals, with case reports linking infections to professional activities. Cat breeders also demonstrate higher risk, correlated with flea infestation in cattery environments, where seroprevalence in cats can exceed 30% and indirectly heightens human exposure through close management. Host-specific factors influence dissemination risk beyond general immunocompromise. , as seen in conditions like , predisposes to bacteremia and systemic spread by impairing splenic clearance of the pathogen. Selective IgA deficiency has been associated with atypical disseminated in otherwise immunocompetent adults, suggesting a role for mucosal immunity in containment, though such cases remain rare. No strong genetic predispositions have been consistently identified in population studies. Environmental and seasonal elements contribute to dynamics. Homes infested with s amplify transmission, as infected feces contaminate scratches, facilitating . Travel to endemic regions, such as the where cat and populations are dense, heightens exposure risk. Cases peak in fall and winter, aligning with indoor cat-human interactions and activity patterns.

Diagnosis

Clinical Evaluation

Clinical evaluation of suspected Bartonella henselae infection begins with a detailed history to identify risk factors, particularly recent exposure to , which is reported in 70-90% of cases involving . Patients should be queried about scratches, bites, or licks from s—especially kittens—occurring 2-8 weeks prior, as well as any travel to endemic areas or underlying immunocompromise, such as infection or , which heightens the risk of severe manifestations. A history of unexplained fever or in the context of cat contact raises suspicion, particularly in children and young adults who account for most cases. On , clinicians look for an inoculation site , typically a 3-5 mm erythematous , pustule, or vesicle on the head, arms, or legs, present in approximately 50-90% of cases but often transient and overlooked by patients. Regional is a hallmark finding, characterized by tender, unilateral nodes greater than 1 cm in size, most commonly in axillary (46%) or (26%) regions, with suppuration occurring in 10-15% of instances. Low-grade fever (in 28-60% of patients) and general may accompany these signs, prompting a thorough fever workup including assessment for in systemic cases. Suspicion for B. henselae is warranted in cases of unexplained fever with recent contact or, in immunocompromised individuals, any vascular proliferative lesion suggestive of bacillary angiomatosis. The differential diagnosis includes mimics such as (from similar zoonotic exposure), (with systemic symptoms), and (causing persistent nodes), necessitating exclusion of these through history and exam. Clinical criteria supporting presumptive include exposure, presence of an inoculation lesion, and regional . Infections are staged as mild (localized to site and nodes), moderate (with systemic symptoms like fever), or severe (disseminated, especially in immunocompromised patients), with monitoring for complications such as nodal formation via serial exams or imaging if suppuration is suspected. confirmation, such as , may follow if clinical suspicion is high but is not part of initial bedside assessment.

Laboratory Methods

Serological testing remains a cornerstone for diagnosing Bartonella henselae infections, with the indirect assay (IFA) serving as the gold standard due to its established reliability in detecting antibodies. The assay measures IgM antibodies, indicative of acute at titers greater than 1:64, and IgG antibodies, suggesting past or ongoing at titers greater than 1:256. As of 2025, IFA demonstrates variable , ranging from 53-100% and 94-97% respectively in recent studies, though performance can vary by patient immune status and disease stage. Polymerase chain reaction () provides direct detection of B. henselae DNA from clinical specimens such as blood, tissue, or s, targeting conserved regions like the 16S rRNA gene or the intergenic transcribed spacer (ITS) region for species-specific identification. Real-time offers improved sensitivity over conventional methods, with reported detection rates of 43-76% in () cases, particularly when applied to lymph node aspirates or biopsies. Interpretation relies on positive amplification confirmed by sequencing or probe hybridization, though negative results do not exclude infection due to intermittent bacteremia. Culture-based methods for B. henselae isolation are challenging owing to the bacterium's fastidious nature, requiring prolonged incubation on enriched agar under 5% CO₂ at 35-37°C for up to 21-45 days. Yield remains low at 20-40%, limiting its routine use, but successful isolation confirms viable organisms and supports susceptibility testing. Histopathological examination of biopsies, such as nodes, often employs the Warthin-Starry silver stain to visualize characteristic clusters of pleomorphic within granulomas or vascular structures. All procedures necessitate biosafety level 2 containment due to the potential for aerosol transmission. Recent molecular advancements enhance diagnostic precision, including whole-genome sequencing (WGS) for strain typing, which distinguishes genotypes like and Houston-1 based on multi-locus sequence typing of housekeeping genes, aiding epidemiological tracking. Multiplex PCR panels developed around 2021 and refined in subsequent years improve detection in complex cases like by simultaneously targeting multiple species alongside other pathogens. As of 2025, multiplex serological assays have been developed to detect antibodies against multiple Bartonella species simultaneously, improving surveillance and in complex cases. Diagnostic challenges include serological with Chlamydia species, potentially leading to false positives in patients with prior chlamydial exposure, and false negatives in early infection when levels are undetectable. Recent 2025 studies underscore the value of quantitative (qPCR) for disseminated cases, where it detects low bacterial loads in blood or tissues with higher sensitivity than alone. Guidelines from the CDC recommend combining clinical evaluation with or for confirmation of B. henselae , particularly in atypical or severe presentations, to balance .

Treatment

Antimicrobial Therapy

The primary antimicrobial therapy for mild cases of (CSD) caused by Bartonella henselae is , administered as 500 mg orally on day 1 followed by 250 mg orally on days 2 through 5 in adults and children weighing more than 45.5 kg. This regimen shortens the duration of swelling by approximately 50%, with significant clinical benefit demonstrated in a randomized placebo-controlled where treated patients showed faster reduction in lymph node volume compared to controls. Alternative therapies include at 100 mg orally twice daily for 4-6 weeks in adults and for cases. For bacillary angiomatosis, at 600 mg orally daily is combined with erythromycin. In severe cases such as , is combined with a (e.g., rifampin) or gentamicin for at least 6 weeks, often requiring surgical intervention. For , trimethoprim-sulfamethoxazole is an effective option, particularly in immunocompromised patients. Though most CSD cases are self-limited. Resistance remains rare but has emerged to in some strains through mutations in 23S rRNA. In pediatric patients, azithromycin dosing is weight-based at 10 mg/kg orally on day 1 followed by 5 mg/kg orally on days 2 through 5 for those weighing 45.5 kg or less; should be avoided in children younger than 8 years due to risk of dental staining. Recent 2024 reviews reinforce the avoidance of beta-lactams in B. henselae infections due to their poor intracellular penetration and limited activity against this facultative intracellular pathogen.

Supportive Care

Supportive care forms the cornerstone of management for most Bartonella henselae infections, particularly (CSD), where the majority of cases in immunocompetent individuals resolve spontaneously without antimicrobial intervention. This approach emphasizes symptom relief, monitoring for progression, and prevention of complications through non-pharmacologic and symptomatic measures. In mild to moderate presentations, such as regional , the focus is on alleviating discomfort and promoting natural resolution, which typically occurs within 2 to 4 months. For , the primary manifestation in , warm compresses applied to the affected nodes help reduce swelling and tenderness. Analgesics, such as ibuprofen at doses of 400-600 mg every 6-8 hours as needed for adults, provide effective relief alongside anti-inflammatory effects. In cases of large, suppurative nodes exceeding 3 cm or causing significant discomfort, ultrasound-guided needle may be performed to drain and alleviate pressure, though incision and drainage is generally avoided to prevent fistula formation. Systemic symptoms like fever, fatigue, and malaise are managed with rest, adequate hydration to maintain , and antipyretics such as acetaminophen or ibuprofen for fever control. Close monitoring is essential to detect complications, including formation, which may require or if suppuration develops. These measures support the body's while minimizing discomfort during the acute phase. In severe or disseminated cases, such as those involving immunocompromised patients or bacillary angiomatosis, hospitalization may be necessary for intravenous fluids to address and imbalances, particularly if oral intake is impaired. For persistent vascular lesions in bacillary angiomatosis, surgical excision serves as an adjunctive procedure for solitary or refractory nodules after initial stabilization. Follow-up involves serial clinical examinations every 2-4 weeks to assess node resolution and symptom progression, with or imaging reserved for unresolved or enlarging to rule out complications like or alternative diagnoses. Patients are advised to return promptly if symptoms worsen, such as increasing size or new fever. Patient education is integral, emphasizing avoidance of further scratches or bites during recovery to prevent reinfection or exacerbation, alongside general practices. Routine use of corticosteroids is not recommended, as they offer no proven benefit and may increase risk without addressing the underlying pathology. Most B. henselae infections resolve without specific intervention, with supportive care alleviating symptoms and reducing associated morbidity in the 10-20% of cases that develop complications like suppuration or prolonged discomfort. Early symptomatic management can shorten the duration of severe pain and improve during recovery.

Prevention

Zoonotic Control Measures

Flea represents the cornerstone of preventing Bartonella henselae from cats to humans, as fleas serve as the primary for spreading the bacterium between cats and subsequently to people via contaminated scratches or flea bites. Monthly topical treatments, such as or applied to cats, have been shown to effectively eliminate fleas and interrupt cycles. Environmental flea sprays and vacuuming of and carpets should complement these treatments to target flea eggs and larvae in the household. Experimental studies demonstrate that consistent flea prevents B. henselae among cats, with products like imidacloprid-flumethrin collars achieving complete prevention in controlled settings. Maintaining cat hygiene is essential to minimize direct transmission risks through scratches or bites. Regular nail trimming reduces the severity of potential injuries, while avoiding rough play—particularly with kittens, which are more likely to scratch—helps prevent exposure to infected saliva or flea feces on claws. Any cat scratches or bites should be washed immediately with soap and water to remove potential contaminants, followed by application of an if available. In households with high-risk individuals, such as those who are immunocompromised, testing cats for B. henselae using or on blood samples may be considered to assess status, though major guidelines like those from the Infectious Diseases Society of America do not recommend routine screening due to lack of proven benefit. If a tests positive for bacteremia, isolation from the owner or enhanced flea control and measures are advised to mitigate zoonotic risk. Declawing cats as a preventive measure for B. henselae transmission is controversial and not routinely recommended by veterinary authorities, as it does not address the underlying vector and raises significant welfare concerns. Alternatives, such as soft nail caps that cover claws without surgical intervention, provide a humane option for reducing risks while preserving natural behavior. Adoption guidelines emphasize selecting cats from reputable sources to lower exposure risks. Shelter cats should be screened for fleas and general prior to , and vulnerable individuals are advised to avoid strays or kittens under one year old, opting instead for adult cats with known histories. The efficacy of these measures is supported by research showing that rigorous flea control can significantly reduce B. henselae bacteremia in cats in endemic areas.

Public Health Strategies

Public health strategies for managing Bartonella henselae infections, primarily manifesting as (CSD), emphasize , education, veterinary interventions, policy measures, and global coordination to mitigate zoonotic transmission from cats and fleas. These approaches aim to reduce incidence at the population level, particularly in high-risk areas like the where prevalence is elevated. efforts in the United States focus on state-level reporting, as CSD is not a nationally notifiable condition. It is reportable in several states, including , where cases must be reported within one working day, and , classified under Category II for prompt notification to health departments. The Centers for Disease Control and Prevention (CDC) monitors national trends through passive , epidemiological studies, and databases such as MarketScan, estimating around 12,000–12,500 annual diagnoses (based on 2005–2013 data) and approximately 500 hospitalizations, predominantly among children under 21. Integration with broader zoonotic networks, including initiatives, enhances tracking of transmissions from companion animals like cats, which serve as primary reservoirs. Education campaigns target both veterinary professionals and the public to promote awareness of transmission risks. Veterinary guidelines, such as those from the European Advisory Board on Cat Diseases (; updated January 2025) and the Companion Animal Parasite Council (CAPC), recommend year-round flea control using topical products like 10% –1% moxidectin to interrupt B. henselae transmission via fleas. Public awareness efforts include resources from the (AAP), which provide parent-oriented materials on recognizing CSD symptoms and preventing scratches from kittens, emphasizing prompt wound care and flea management in households with cats. Veterinary interventions prioritize flea prevention and among . Routine flea treatments are advocated to reduce bacteremia in , as fleas are the primary for B. henselae between felines, with studies showing that consistent application of ectoparasiticides can lower risk. No against B. henselae is currently available for , though experimental has explored of recombinant proteins like P26. Spay/neuter programs target stray and populations to curb and limit reservoir expansion, as these groups exhibit higher infection rates; for instance, prevalence studies in spay/neuter cohorts in and the U.S. highlight the role of such initiatives in reducing zoonotic exposure. Policy measures include animal control regulations to manage and precautionary screening in contexts. Local and state laws often mandate trapping and relocation or of cats to decrease environmental reservoirs, with trap-neuter-return (TNR) programs promoted in some regions to humanely stabilize populations. For safety, while no FDA-licensed screening test exists for B. henselae in donors, identifies ownership as a , prompting recommendations for enhanced donor history assessments following documented post-transfusion transmissions in animal models. Globally, efforts align with (WHO) frameworks for zoonotic disease control, which integrate veterinary and human health surveillance to address emerging pathogens like B. henselae, though specific programs focus more broadly on vector-borne threats. In , recent studies (as of 2025) have characterized B. henselae prevalence in fleas, foxes, and blood donors using PCR-based detection in ectoparasites and wildlife. Key challenges include underdiagnosis due to the fastidious nature of B. henselae, which complicates culture and , leading to reliance on indirect methods with variable sensitivity. The absence of a commercial hinders eradication efforts, but ongoing research into immunization, including strain-specific protection studies, offers potential for future breakthroughs.

History

Discovery and Isolation

The etiology of (CSD), a condition characterized by regional following cat scratches or bites, remained elusive until the early when researchers identified pleomorphic in affected nodes using the Warthin-Starry silver , suggesting a bacterial cause. These acid-fast-negative organisms were observed in specimens from CSD patients, providing the first histological evidence of an infectious agent, though cultivation proved challenging due to the bacterium's fastidious nature. This recognition in the 1980s laid the groundwork for linking CSD to a novel pathogen. A pivotal advancement occurred in 1990 when Relman et al. applied 16S rRNA (PCR) amplification and sequencing to uncultured from skin lesions of AIDS patients with bacillary angiomatosis, identifying the organism as a member of the alpha-proteobacteria closely related to Rochalimaea quintana. This molecular approach revealed the same bacterium in CSD lymph nodes, establishing its role in both conditions via silver stain identification in tissues. Concurrently, isolates from blood and tissues of patients with septicemia, bacillary angiomatosis, and peliosis were cultured on artificial media such as under 5% CO2, leading to the proposal of the species Rochalimaea henselae in 1992 based on phenotypic, enzymatic, and DNA hybridization analyses. In 1993, Dolan et al. reported the first isolation of R. henselae from a CSD patient's lymph node aspirate, cultured on heart infusion agar with 5% rabbit blood, confirming its direct causation of typical CSD lymphadenitis in immunocompetent individuals. That same year, phylogenetic analysis using 16S rRNA sequencing prompted the reclassification of Rochalimaea species into the genus Bartonella, with B. henselae receiving nomenclatural priority due to its historical precedence. Epidemiological studies further solidified the domestic cat as the primary reservoir, with B. henselae isolated from the blood of cats owned by CSD patients using enriched blood agar media, and PCR detection in cat fleas (Ctenocephalides felis) confirming arthropod involvement in transmission among felines.

Key Research Milestones

In 2003, the complete genome sequence of Bartonella henselae strain Houston-1 was published, spanning 1,931,047 base pairs and revealing the virB locus, which encodes components of a type IV secretion system critical for bacterial . This sequencing effort identified key genetic elements, including 1,513 predicted protein-coding sequences, providing foundational insights into the pathogen's mechanisms of host interaction and . During the 2010s, studies further elucidated the type IV secretion system's role in B. henselae , with Schulein et al. demonstrating that a bipartite signal mediates the transfer of effector proteins into human endothelial cells, enabling bacterial invasion and anti-apoptotic effects. Concurrently, animal models, including systems, were refined to investigate , revealing how the system facilitates erythrocyte invasion and persistent bacteremia in reservoir hosts. In the 2020s, key advances included a 2023 CDC report estimating approximately 12,500 annual B. henselae infections and 500 hospitalizations in the United States, emphasizing for improved . Diagnostic progress accelerated with 2024 developments in multiplex real-time assays targeting B. henselae, enabling rapid detection in clinical samples alongside other tick-borne pathogens. Therapeutic advancements were supported by a 2024 analysis confirming azithromycin's superiority in rapidly reducing volume in compared to no treatment. Ongoing efforts have addressed diagnostic gaps through improved specificity via recombinant protein-based enzyme immunoassays. Molecular studies have linked specific genotypes, such as Houston-1 variants, to increased severity in immunocompromised hosts.

References

  1. [1]
    About Bartonella henselae - CDC
    May 15, 2024 · B. henselae infection (CSD) occurs most often in children under the age of 15. Though more common in the southeast, CSD occurs throughout the United States.
  2. [2]
    Cat Scratch Disease - StatPearls - NCBI Bookshelf
    Cat scratch disease is an illness caused by an intracellular gram-negative rod known as Bartonella henselae. It affects the lymph nodes draining the area where ...Continuing Education Activity · Introduction · Etiology · Epidemiology
  3. [3]
    Cultivation of Bartonella henselae in an Ixodes ricinus cell line ... - NIH
    Sep 1, 2025 · The Bartonella genus belongs to the Bartonellaceae family, Rhizobiales order and Alphaproteobacteria class and comprises Gram-negative ...Missing: taxonomy | Show results with:taxonomy
  4. [4]
    Intruders below the Radar: Molecular Pathogenesis of Bartonella spp
    ... BadA-mediated adhesion to endothelial cells ... Bartonella henselae and Bartonella quintana adherence to and entry into cultured human epithelial cells.
  5. [5]
    Molecular Mechanisms of Bartonella and Mammalian Erythrocyte ...
    Dec 12, 2018 · Bartonella use LPS, flagella, and BadA orthologs against phagocytes and complement activation (Step 1). Erythrocyte adhesion is mediated by ...Step 2: Erythrocyte Adhesion · Step 3: Erythrocyte Invasion · Step 4: Erythrocyte...
  6. [6]
    Strategy for identification & characterization of Bartonella henselae ...
    Bartonella henselae is a fastidious gram-negative bacterium usually causing self limiting infections in immunocompetent individuals but often causes ...
  7. [7]
    Bartonella henselae - microbewiki
    Aug 20, 2010 · Higher order taxa: Domain: Bacteria, Phylum: Proteobacteria, Class: Alphaproteobacteria, Order: Rhizobiales, Family: Bartonellaceae (1). Species ...
  8. [8]
    Growth Characteristics of Bartonella henselae in a Novel Liquid ...
    We have developed a liquid growth medium that supports reproducible in vitro growth (3-h doubling time and a growth yield of approximately 5 × 10 8 CFU/ml)
  9. [9]
    Characterization of Clinical Isolates of Bartonella henselae Strains ...
    Mar 28, 2018 · ... colonies on the agar plate takes a long time. On the other hand, Bartonella species grow more rapidly with cell culture–based systems (6).
  10. [10]
    Bartonella henselae - VetBact
    Mar 22, 2023 · Bartonella henselae, G- (weakly stained). Metabolism: Aerobic. Catalase/Oxidase: v/-. Other Enzymes: Tryptophanase -, urease -. Biochemical ...
  11. [11]
    The louse-borne human pathogen Bartonella quintana is a genomic ...
    We present the complete genomes of two human pathogens, Bartonella quintana (1,581,384 bp) and Bartonella henselae (1,931,047 bp).
  12. [12]
    Genome Rearrangements, Deletions, and Amplifications in the ...
    Here, we have analyzed the natural variation in gene content and genome structure of 38 Bartonella henselae strains isolated from cats and humans by comparative ...<|separator|>
  13. [13]
    Bartonella Adhesin A Mediates a Proangiogenic Host Cell Response
    BadA mediates the binding of B. henselae to extracellular matrix proteins and to endothelial cells, possibly via β1 integrins, but prevents phagocytosis.
  14. [14]
    The VirB type IV secretion system of Bartonella henselae mediates ...
    Feb 19, 2004 · We conclude that the VirB T4SS is a major virulence determinant of B. henselae, required for targeting multiple endothelial cell functions exploited by this ...
  15. [15]
    16S/23S rRNA Intergenic Spacer Regions for Phylogenetic Analysis ...
    Genotypic diversity among Bartonella strains was assessed using RFLP analysis of PCR-amplified ITS and allowed the differentiation of seven profiles among 11 ...Missing: virulence | Show results with:virulence
  16. [16]
    Recommendations for Treatment of Human Infections Caused by ...
    Jun 1, 2004 · The objective of this minireview is to summarize the antibiotic treatment recommendations for the different infections caused by Bartonella species.
  17. [17]
    About Bartonella - CDC
    Mar 3, 2025 · Overview ; Image of a flea. B. henselae is transmitted by the scratch of domestic or feral cats. Cats can have fleas that carry the bacteria.Bartonella henselae · Bartonella bacilliformis · Bartonella quintana · Site Index
  18. [18]
    [PDF] Cat Scratch Disease and Other Zoonotic Bartonella Infections
    The genus Bartonella contains more than 30 species of facultative intracellular bacteria that circulate in mammals and other vertebrates, including humans.
  19. [19]
    Viability and Desiccation Resistance of Bartonella henselae in ...
    Jul 18, 2023 · We investigated the ability of B. henselae to survive in fluid matrices chosen to mimic potential environmental sources of infective materials.
  20. [20]
    (PDF) LICE-BORNE DISEASES - ResearchGate
    By contrast, B. henselae infects both humans and cats; 30-60% of domestic cats in ... Bartonella henselae. Proc Natl Acad Sci U S A. 2004;101:9716–21. 72. B ...
  21. [21]
    Bartonella infections in cats and dogs including zoonotic aspects
    Dec 4, 2018 · In Europe, Bartonella antibody prevalence in cats ranges from 0% in Norway [63] to 71.4% in Spain [64] (Table 2). Bacteremic prevalence rates ...
  22. [22]
    Bartonella henselae (Cat-Scratch Disease) - DynaMed
    Jul 14, 2024 · The main mode of cat-scratch disease transmission is from cat to human via a scratch or bite. 1. ,. 2. ,. 3.
  23. [23]
    [PDF] Bartonella Species - AABB
    Bartonella henselae is a common human pathogen. 2.6 | Common human exposure routes. • Bartonella henselae is commonly transmitted to humans by a saliva ...
  24. [24]
    Bartonella quintana Infection in Kidney Transplant Recipients ... - CDC
    Nov 20, 2024 · Bartonella infection has previously been found in solid organ transplant recipients (14,15). In most of those cases, B. henselae was the ...
  25. [25]
    Bartonella henselae - Pathogen Safety Data Sheets - Canada.ca
    SURVIVAL OUTSIDE HOST: Unknown. SECTION V - FIRST AID / MEDICAL. SURVEILLANCE: Monitor for symptoms. Identification can be done by histology tests of lymph ...
  26. [26]
  27. [27]
  28. [28]
  29. [29]
  30. [30]
  31. [31]
  32. [32]
  33. [33]
  34. [34]
  35. [35]
  36. [36]
  37. [37]
  38. [38]
    Cat Scratch Disease (Cat Scratch Fever) - Medscape Reference
    Mar 5, 2024 · Seizures, which occur in as many as 80% of ... One episode of cat scratch disease confers lifelong immunity to children and adolescents.
  39. [39]
    Bartonella henselae (Cat-Scratch Disease) | Red Book Online
    Cat scratch disease, the predominant clinical manifestation of ... primary lesion to the appearance of lymphadenopathy is 12 days (range, 7 to ...
  40. [40]
    Cat-Scratch Disease in the United States, 2005–2013 - CDC
    Oct 10, 2016 · Incidence of CSD was highest among those who lived in the southern United States (6.4 cases/100,000 population) and among children 5–9 years of ...Missing: percentage | Show results with:percentage
  41. [41]
    Dermatologic Manifestations and Update of Cat Scratch Disease
    Cat scratch disease is a relatively common cause of chronic (three weeks or longer) lymphadenopathy, with 80% of cases occurring in children and adolescents.
  42. [42]
    Bacillary Angiomatosis - StatPearls - NCBI Bookshelf
    Bacillary angiomatosis is caused by two species of Bartonella genus namely Bartonella henselae and Bartonella quintana. The clinical spectrum of bacillary ...Etiology · Epidemiology · Pathophysiology · Evaluation
  43. [43]
    Bartonellosis: Adult and Adolescent OIs | NIH - Clinical Info .HIV.gov
    Nov 14, 2023 · Osteomyelitis is usually caused by B. quintana, and only B. henselae causes bacillary peliosis hepatis. ... Although isolated organs can appear to ...
  44. [44]
    Molecular Epidemiology of Bartonella Infections in Patients with ...
    Dec 25, 1997 · Two species, Bartonella henselae and B. quintana, have been associated with bacillary angiomatosis, but culture and speciation are difficult.Missing: review | Show results with:review
  45. [45]
    Bartonellosis (Bartonella Infection) - Medscape Reference
    Aug 16, 2024 · Peliosis hepatis is caused by B henselae. Mortality is low but morbidity is caused by direct organ involvement of bacillary angiomatosis; ...
  46. [46]
    Bartonella, a Common Cause of Endocarditis: a Report on 106 ...
    Feb 19, 2015 · Bartonella spp. are fastidious bacteria that cause blood culture-negative endocarditis and have been increasingly reported.
  47. [47]
    Endocarditis caused by Bartonella - UpToDate
    Apr 19, 2024 · In the United States, Bartonella is one of the most common, if not the most common, cause of culture-negative endocarditis. ... henselae, B.
  48. [48]
    The Brief Case: Bartonella henselae Endocarditis—a Case of ... - NIH
    Aug 26, 2019 · henselae and B. quintana have a global distribution and are associated with culture-negative endocarditis in approximately 12% to 28% of cases.
  49. [49]
    Cat Scratch Disease - EyeWiki
    Sep 11, 2025 · Cat Scratch Disease ... Cases of peripapillary CNV secondary to Bartonella henselae infection have been reported but are extremely rare.<|control11|><|separator|>
  50. [50]
    Neurobartonelloses: emerging from obscurity! - Parasites & Vectors
    Oct 5, 2024 · Post-COVID reactivation of latent Bartonella henselae infection: a case report and literature review. BMC Infect Dis. 2024;24:422. Article ...
  51. [51]
    Neurologic complications of Bartonella henselae infection - PubMed
    Both of these diseases are associated with neurologic complications, particularly encephalopathy. B. henselae may also cause bacteremia and endocarditis, and ...
  52. [52]
    Bartonellosis in transplant recipients: A retrospective single center ...
    Bartonellosis is a rare but challenging condition to diagnose with a spectrum of clinical presentations in the immunocompromised host.
  53. [53]
    Bartonella Infection in Immunocompromised Hosts - PubMed Central
    Empiric data have shown that Bartonella initially evades the innate immune system because its surface molecules are not recognized by TLR-4 on dendritic cells ...
  54. [54]
    Cat-Scratch Disease in the United States, 2005–2013 - PMC
    Average annual incidence was 4.5 outpatient diagnoses/100,000 population ... Bartonella henselae infections in pet cats in four regions of the United States.
  55. [55]
    Bartonella spp. Infections Identified by Molecular Methods, United ...
    Mar 3, 2023 · In the United States, B. henselae is the most common pathogenic Bartonella spp.; ≈12,500 cases of infection and 500 hospitalizations occur ...
  56. [56]
    Veterinary Guidance for Bartonella - CDC
    May 15, 2024 · Bartonella henselae bacteremia has been documented in 30-40% of domestic and adopted shelter cats. Kittens showing evidence of infection were ...
  57. [57]
    The Global Molecular Prevalence of Bartonella spp. in Cats and ...
    Nov 8, 2023 · Based on 20.133 cats and 9.824 dogs, the global prevalence estimates were 15.3% and 3.6%. The heterogeneity was significantly high in both species.
  58. [58]
    Bartonella henselae: A challenging diagnosis with a bright future
    Oct 21, 2025 · Bartonella species were isolated from 7.2% (50/690) of all the cats examined. No Bartonella species were isolated from the cats in Sapporo or ...
  59. [59]
    Estimated prevalence and genetic diversity of Bartonella species in ...
    Oct 31, 2025 · within countries, with a prevalence rate ranging from 5.7% to 65%, with none of the included countries reported the absence of Bartonella spp.
  60. [60]
    Molecular Detection of Rickettsia felis, Bartonella henselae, and B ...
    Nov 1, 2011 · Bartonella henselae DNA was detected in 28 (13.4%) fleas in this study. Analysis of pap31 sequences differentiates the bartonellae into two ...
  61. [61]
    Epidemiology of Bartonella henselae infection in pet and stray cats ...
    Feb 1, 2024 · Bartonella spp. was detected in 31 cats (16.4%), and subsequent genotyping at the eight loci revealed B. henselae in all cases. Thirty complete ...
  62. [62]
    Did Bartonella henselae contribute to the deaths of two veterinarians?
    Jun 12, 2015 · Veterinary workers are at occupational risk for acquiring bartonellosis. As an emerging, and incompletely understood, stealth bacterial pathogen ...Missing: breeders | Show results with:breeders
  63. [63]
    Seroprevalence of Bartonella henselae in cattery cats - PubMed
    Flea infestation was the most important risk factor for high B. henselae seroprevalence in the catteries we surveyed. Individual cat titres were comparable ...Missing: breeders | Show results with:breeders
  64. [64]
    Sickle Cell Disease and Bartonella Spp. Infection - PMC
    Jun 30, 2012 · infection rate as they present with inflammation, endothelial activation, asplenia ... Blood donor infected with Bartonella henselae. Transfus Med ...
  65. [65]
    Disseminated cat-scratch disease in an adult with selective IgA ...
    Selective IgA deficiency is a relatively common immunoglobulin deficiency ... Beyond cat scratch disease: widening spectrum of Bartonella henselae infection.
  66. [66]
    Cat-scratch Disease - AAFP
    Jan 15, 2011 · Cat-scratch disease is a common infection that usually presents as tender lymphadenopathy. It should be included in the differential diagnosis of fever of ...
  67. [67]
    Cat Scratch Disease (Cat Scratch Fever) Clinical Presentation
    Mar 5, 2024 · The diagnosis is based on characteristic filling defects in the liver, spleen, or both as detected by ultrasonography, CT scanning, and a ...
  68. [68]
    Clinical Guidance for Bartonella henselae - CDC
    May 15, 2024 · People become infected with Bartonella henselae from the scratch of domestic or feral cats, particularly kittens. Cats can have fleas that carry B. henselae ...
  69. [69]
    Diagnosis of Cat Scratch Disease with Detection of Bartonella ...
    Presence of at least two criteria among a history of cat contact, presence of B. henselae antibodies, and histology compatible with CSD. b. Presence of less ...
  70. [70]
    Clinical utility of indirect fluorescent assay for IgA class antibodies ...
    The IFA for anti-B. heselae IgG (IgG-IFA) is regarded as the gold standard for detecting antibodies against B. henselae. However, despite its high specificity, ...
  71. [71]
    Bartonella henselae (Cat Scratch) Antibodies, IgG & IgM by IFA
    May assist in diagnosing cat scratch disease in patient with typical signs and symptoms and a compatible exposure history.
  72. [72]
    Seroprevalence of antibodies to Bartonella henselae in patients with ...
    The data show that the seroprevalence of antibodies to B. henselae in German individuals is high (30%). Low antibody levels are not sufficient evidence of ...
  73. [73]
    Test ID: BARRP Bartonella, Molecular Detection, PCR, Varies
    Mayo Clinic Laboratories has developed a real-time PCR test that permits rapid identification of Bartonella species. The assay targets a unique sequence of the ...
  74. [74]
    Bartonella henselae Infection: An Uncommon Mimicker of ...
    Jan 17, 2013 · PCR in blood or tissue specimens is the most effective way to exclude bartonellosis; however this method lacks sensitivity (43–76%) [3]. On ...<|control11|><|separator|>
  75. [75]
    Bartonellosis (Bartonella Infection) Workup - Medscape Reference
    Aug 16, 2024 · Bartonella quintana more commonly is cultured from the blood compared to bartonella henselae, especially in acute B quintana infection.
  76. [76]
    Cat Scratch Disease (Cat Scratch Fever) Workup
    Mar 5, 2024 · An antibody titer that exceeds 1:64 suggests recent Bartonella infection. Paired acute and convalescent sera (drawn 6 wk apart) showing a 4-fold ...Approach Considerations · Serologic Testing · Biopsy · Skin Testing
  77. [77]
    Bartonella Species | Johns Hopkins ABX Guide
    The preferred drugs are doxycycline or azithromycin, and for serious infections, +/- rifampin. For chronic infections, consider monitoring serologic responses.
  78. [78]
    Draft genomes of 16 Bartonella henselae strains from cats in ... - NIH
    Oct 17, 2023 · Here, we report the whole genome sequences of 16 strains isolated from cats in Valdivia city, Southern Chile.
  79. [79]
    Laboratory Diagnosis of 37 Cases of Bartonella Endocarditis Based ...
    May 19, 2021 · We developed an enzyme immunoassay (EIA) and a novel multiplex real-time PCR assay, utilizing Bartonella genus-specific, B. henselae-specific, and B. quintana- ...
  80. [80]
    Serological cross-reactions between Bartonella and Chlamydia ...
    This work highlights the possibility that cases of infective Bartonella endocarditis are erroneously diagnosed as chlamydial infections.
  81. [81]
    [PDF] Seropositivity of Bartonella henselae Among Suspected Cat Scratch ...
    Jun 30, 2025 · Result showed that 86% of CSD cases were PCR positive with B. henselae and none of the non CSD group were PCR positive, yielding a ...<|control11|><|separator|>
  82. [82]
    Skin and Soft Tissue Infections - IDSA
    Jul 15, 2014 · Serological testing supports the diagnosis, although there is cross-reactivity between B. henselae and B. quintana as well as with a few other ...Abstract · Recommendations (Abridged) · Introduction · Full Recommendations
  83. [83]
    Recommendations for Treatment of Human Infections Caused by ...
    Treatment with an azithromycin regimen (500 mg orally [p.o.] on day 1 and 250 mg p.o. on days 2 to 5 as single daily doses) could be an alternative for patients ...
  84. [84]
    Prospective randomized double blind placebo-controlled evaluation ...
    Conclusions: Treatment of patients with typical cat-scratch disease with oral azithromycin for five days affords significant clinical benefit as measured by ...
  85. [85]
    Bartonellosis (Bartonella Infection) Treatment & Management
    Aug 16, 2024 · Rifampin or gentamicin for at least 14 days should be included in the treatment of Bartonella endocarditis in combination with doxycycline for ...
  86. [86]
    Cat Scratch Disease (Cat Scratch Fever) Treatment & Management
    Mar 5, 2024 · Antibiotic Treatment · Rifampin - Efficacy of 87% · Ciprofloxacin - Efficacy of 84% · Gentamicin intramuscularly - Efficacy of 73% · Trimethoprim/ ...
  87. [87]
    Molecular Characterization of Resistance to Macrolides in ... - NIH
    For B. henselae, potential mechanisms of resistance to macrolides are not known, and the objective of the present study was to select in vitro erythromycin- ...
  88. [88]
    Cat Scratch Fever: Causes, Symptoms & Treatment - Cleveland Clinic
    It causes swollen lymph nodes, bumps on your skin and a fever. B. henselae can infect you if a cat bites or scratches you or licks an open wound you have.Missing: criteria | Show results with:criteria
  89. [89]
    Bartonella henselae (Cat-Scratch Disease) | Red Book
    Cats are the natural reservoir for B henselae, with a seroprevalence of 30% to 40% in domestic and adopted shelter cats in the United States. Other animals ...
  90. [90]
    EM@3AM: Cat-Scratch Disease - emDocs
    Oct 18, 2025 · This patient is exhibiting typical findings of cat scratch disease (CSD), caused by the bacteria Bartonella henselae following a cat bite or ...
  91. [91]
    Bacillary Angiomatosis Treatment & Management
    Mar 24, 2025 · Treatment for bacillary angiomatosis typically involves erythromycin or doxycycline, administered for a minimum duration of 3 months. In cases ...<|separator|>
  92. [92]
    Cat scratch disease neuroretinitis: A case report - ScienceDirect.com
    Systemic corticosteroids are not recommended in routine use for patients with neuroretinitis because of uncertain benefit and significant morbidity ...
  93. [93]
    Evaluation of topical application of 10% imidacloprid–1% moxidectin ...
    Apr 15, 2010 · Bartonella henselae lives within infected fleas for up to 9 days and ... Immunofluorescent detection of intraerythrocytic Bartonella henselae ...
  94. [94]
    The efficacy of a selamectin (Stronghold®) spot on treatment in the ...
    Jan 14, 2015 · None of the selamectin-treated cats became positive during the study. It was concluded that Stronghold® spot on administered to cats was ...
  95. [95]
    Cat Scratch Disease (CSD) - VCA Animal Hospitals
    The flea ingests blood containing Bartonella from an infected cat, then the bacteria reproduce in the flea, and then shed in the feces.
  96. [96]
    A flea and tick collar containing 10% imidacloprid and 4.5 ...
    Jan 25, 2013 · A flea and tick collar containing 10% imidacloprid and 4.5% flumethrin prevents flea transmission of Bartonella henselae in cats. Michael R ...
  97. [97]
    What do we really know about feline bartonellosis? (Proceedings)
    Bartonella henselae is transmitted among cats by fleas. Viable Bartonella organisms are excreted in flea feces and cats are likely inoculated via ...<|control11|><|separator|>
  98. [98]
    GUIDELINE for Feline bartonellosis - ABCD cats & vets
    Jan 10, 2025 · henselae is naturally transmitted among cats by the flea Ctenocephalides felis felis, or by flea faeces. Bartonella henselae was experimentally ...Epidemiology · Prevalence · Clinical Signs
  99. [99]
    Position Statement on Declawing Cats - ASPCA
    The ASPCA is strongly opposed to declawing cats. The ASPCA does not perform declaw surgeries and supports and utilizes behavioral and environmental ...<|control11|><|separator|>
  100. [100]
    Cat Scratch Disease: A Bacterial Infection - Science
    They were best seen with the Warthin-Starry silver impregnation stain. ... Newly discovered viruses suggest 'German measles' jumped from animals to humans.<|control11|><|separator|>
  101. [101]
    The Agent of Bacillary Angiomatosis | NEJM
    Dec 6, 1990 · The causative agent of cat scratch disease was first visualized in 1983 with the Warthin—Starry silver stain but has resisted ...
  102. [102]
    Rochalimaea henselae sp. nov., a cause of septicemia, bacillary ...
    All except one isolate, which was Rochalimaea quintana, were determined to belong to a newly proposed species, Rochalimaea henselae sp. ... 1990 Dec 6;323(23): ...
  103. [103]
    Syndrome of Rochalimaea henselae Adenitis Suggesting Cat ...
    Mar 1, 1993 · Objective: To describe a clinical syndrome of cat scratch disease caused by Rochalimaea henselae, including methods for isolation of the ...
  104. [104]
    A bipartite signal mediates the transfer of type IV secretion ... - PNAS
    We exemplarily show that the C terminus of such a conjugative relaxase mediates protein transfer through the Bartonella henselae VirB/VirD4 system into HEC.
  105. [105]
    Evaluation of the available animal models for Bartonella infections
    This review examines the current state of available animal models by assessing the success of various model species and strains in Bartonella infection.Missing: underdiagnosis vaccine immunization
  106. [106]
    A molecular toolbox for fast and convenient diagnosis of emerging ...
    Jan 25, 2024 · In this paper, a collection of four real-time PCR assays is designed to detect as few as ten copies of target DNA of Rickettsia spp., Bartonella ...
  107. [107]
    Coinfection with Bartonella clarridgeiae and Bartonella henselae ...
    An epidemiologic study of Bartonella infection in domestic French cats revealed that of 436 cats sampled, 5 cats (1.1%) were coinfected with B. henselae and B.
  108. [108]
    Bartonella henselae Vaccines - Creative Biolabs
    The studies have shown that two genotypes of B. henselae strains (type I and type II) can co-infect the feline host and lead to immune reaction to B. henselae ...
  109. [109]
    Bartonella henselae: A challenging diagnosis with a bright future
    Oct 16, 2025 · Bartonella henselae is a fastidious, facultative intracellular, Gram-negative bacterium that causes Cat Scratch Disease (CSD), a zoonosis in ...<|separator|>
  110. [110]
    Molecular epidemiology of Bartonella henselae infection in human ...
    Bartonella henselae causes severe disease in immunocompromised individuals. B. henselae was isolated from 12 human immunodeficiency virus (HIV)-infected ...